You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 11, 2025

PROSTASCINT Drug Profile


✉ Email this page to a colleague

« Back to Dashboard


Recent Clinical Trials for PROSTASCINT

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Molecular Insight Pharmaceuticals, Inc.Phase 1
David M. Schuster, MDPhase 2
National Cancer Institute (NCI)Phase 2

See all PROSTASCINT clinical trials

Recent Litigation for PROSTASCINT

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
AbbVie Inc. v. Alvotech hf.2021-05-28
Alvotech USA Inc. v. Abbvie Inc2021-05-11
AbbVie Inc. v. Alvotech hf.2021-04-27

See all PROSTASCINT litigation

PTAB Litigation
PetitionerDate
2017-12-20

See all PROSTASCINT litigation

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for PROSTASCINT Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for PROSTASCINT Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for PROSTASCINT Derived from Patent Text Search

These patents were obtained by searching patent claims

Market Dynamics and Financial Trajectory for ProstaScint

Introduction

ProstaScint, also known as ({}^{111})In-capromab pendetide, is a radiolabeled monoclonal antibody used primarily for the imaging of prostate cancer. Understanding its market dynamics and financial trajectory is crucial for investors, healthcare providers, and patients alike.

Historical Financial Performance

In the early 2000s, ProstaScint was a significant contributor to the revenue of Cytogen, the biopharmaceutical company that developed and marketed the drug. For the first quarter of 2008, Cytogen reported a revenue increase of 9.6% compared to the same period in 2007, with ProstaScint sales reaching $2.6 million, up from $2.5 million in the previous year[1].

Despite the revenue growth, Cytogen faced financial challenges, including a net loss of $5.9 million in the first quarter of 2008, which was higher than the $4.8 million net loss in the same period of 2007. This financial situation was partly mitigated by a $3.9 million net litigation settlement with AMAG Pharmaceuticals in 2007[1].

Market Trends in Prostate Cancer Therapeutics

The prostate cancer therapeutics market has been dynamic and growing. From 2010 to 2020, the market saw a significant increase, driven by factors such as the rising incidence of prostate cancer, the launch of innovative drugs, and an increasing older male population. The market was expected to grow at a CAGR of 9% during this period[4].

Role of ProstaScint in Prostate Cancer Diagnosis

ProstaScint is used in the diagnostic workup for patients with rising prostate-specific antigen (PSA) levels after prostatectomy. It helps in identifying the sites of recurrence or metastasis. However, studies have shown that while ProstaScint can detect disease outside the prostate bed, its positive predictive value is relatively low, at around 27%[2].

Competitive Landscape

The prostate cancer therapeutics market is highly competitive, with several major players such as AstraZeneca, Bristol Myers-Squibb, and Johnson & Johnson. These companies have been launching new products and expanding their product pipelines, which has impacted the market share of existing drugs like ProstaScint. For instance, AstraZeneca's market share in the prostate cancer therapeutics market was expected to decrease by 19% by 2020 due to the entry of new players and drugs[4].

Impact of Regulatory and Market Changes

The acquisition of Cytogen by EUSA Pharma in 2008 marked a significant change in the ownership and potentially the marketing strategy for ProstaScint. Such changes can affect the drug's market presence and financial performance. Additionally, regulatory approvals and new clinical guidelines can influence the use and reimbursement of diagnostic agents like ProstaScint[1].

Future Outlook and Market Growth

The broader cancer biologics market, which includes diagnostic and therapeutic agents, is expected to grow significantly. By 2028, the cancer biologics market is projected to reach $168.75 billion, growing at a CAGR of 9.6%. This growth is driven by expanding indications, combination therapies, and advances in biotechnology[3].

Financial Implications for ProstaScint

Given the competitive landscape and the evolving market trends, the financial trajectory for ProstaScint is likely to be influenced by several factors:

  • Competition from New Diagnostic Tools: The emergence of new diagnostic techniques, such as those targeting prostate-specific membrane antigen (PSMA), could potentially reduce the market share of ProstaScint[5].
  • Regulatory and Reimbursement Changes: Changes in regulatory approvals and reimbursement policies can significantly impact the drug's revenue.
  • Integration with New Therapies: The integration of ProstaScint with new therapeutic approaches, such as combination therapies, could enhance its value and market position.

Key Takeaways

  • ProstaScint has historically contributed to the revenue of its parent company, despite financial challenges.
  • The prostate cancer therapeutics market is dynamic and growing, driven by new drugs and an increasing patient population.
  • ProstaScint's role in diagnosis is critical, but its positive predictive value is relatively low.
  • The competitive landscape and regulatory changes can significantly impact the drug's market presence and financial performance.
  • The broader cancer biologics market is expected to grow substantially, driven by advances in biotechnology and expanding indications.

FAQs

Q: What is ProstaScint used for? A: ProstaScint, or ({}^{111})In-capromab pendetide, is used for the imaging of prostate cancer, particularly in patients with rising PSA levels after prostatectomy.

Q: How did ProstaScint impact Cytogen's financial performance in 2008? A: ProstaScint sales contributed to a 9.6% increase in Cytogen's revenue for the first quarter of 2008, but the company still reported a net loss due to other financial factors.

Q: What are the market trends affecting ProstaScint? A: The market is influenced by the launch of new diagnostic and therapeutic agents, changes in regulatory approvals, and shifts in reimbursement policies.

Q: How competitive is the prostate cancer therapeutics market? A: The market is highly competitive with major players like AstraZeneca, Bristol Myers-Squibb, and Johnson & Johnson, which can impact the market share of existing drugs.

Q: What is the future outlook for the cancer biologics market? A: The cancer biologics market is expected to grow significantly, reaching $168.75 billion by 2028, driven by advances in biotechnology and expanding indications.

Sources

  1. AuntMinnie: ProstaScint sales boost Cytogen's Q1
  2. PubMed: Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan
  3. The Business Research Company: Cancer biologics Global Market Report 2024
  4. MarketsandMarkets: Prostate Cancer Therapeutics Market
  5. Journal of Nuclear Medicine: Optimization of every step for optimal patient outcomes

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.